e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review

e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review

  • Products Id :- GDPH82612FSA
  • |
  • Pages: 51
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

e-Therapeutics Plc (ETX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.


e-Therapeutics Plc (e-Therapeutics) is a drug discovery and development company with focus on the treatment of cancer and neurodegeneration. It has a proprietary discovery platform based on network pharmacology and chemical biology for the discovery of drugs. The company focuses on immuno-oncology to tackle drug resistance in targeted cancer therapies and anti-infectives. It's under development drugs include ETS-2300, ETS-2400, ETS-3100, ETS-5200, ETS-6700. e-Therapeutics has development centers in Oxford and Newcastle. The company operates through one subsidiary, InRotis Technologies Limited. e-Therapeutics is headquartered in Long Hanborough, England, the UK.

e-Therapeutics Plc Key Recent Developments

Mar 27,2018: e-therapeutics: Full Year Results 2018

Nov 01,2017: e-Therapeutics: Appointment of Director

Sep 26,2017: e-Therapeutics: Interim Results for the 6 Months Ended 31 July 2017

Jul 27,2017: Edison issues update on e-Therapeutics (ETX)

Jul 24,2017: e-Therapeutics Announces Outcome of Strategic Review and Future Plans

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

e-Therapeutics Plc-Key Facts 5

e-Therapeutics Plc-Key Employees 6

e-Therapeutics Plc-Key Employee Biographies 7

e-Therapeutics Plc-Major Products and Services 8

e-Therapeutics Plc-History 9

e-Therapeutics Plc-Company Statement 10

e-Therapeutics Plc-Locations And Subsidiaries 11

Head Office 11

Other Locations & Subsidiaries 11

Section 2-Company Analysis 12

Company Overview 12

e-Therapeutics Plc-Business Description 13

e-Therapeutics Plc-SWOT Analysis 14

SWOT Analysis-Overview 14

e-Therapeutics Plc-Strengths 14

e-Therapeutics Plc-Weaknesses 15

e-Therapeutics Plc-Opportunities 16

e-Therapeutics Plc-Threats 17

e-Therapeutics Plc-Key Competitors 18

Section 3-Company Financial Ratios 19

Financial Ratios-Capital Market Ratios 19

Financial Ratios-Annual Ratios 20

Performance Chart 22

Financial Performance 22

Financial Ratios-Interim Ratios 23

Financial Ratios-Ratio Charts 24

Section 4-Company's Lifesciences Financial Deals and Alliances 25

e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26

e-Therapeutics Plc, Recent Deals Summary 27

Section 5-Company's Recent Developments 28

Mar 27, 2018: e-therapeutics: Full Year Results 2018 28

Nov 01, 2017: e-Therapeutics: Appointment of Director 33

Sep 26, 2017: e-Therapeutics: Interim Results for the 6 Months Ended 31 July 2017 34

Jul 27, 2017: Edison issues update on e-Therapeutics (ETX) 39

Jul 24, 2017: e-Therapeutics Announces Outcome of Strategic Review and Future Plans 40

Apr 19, 2017: e-Therapeutics: Full Year Results 43

Apr 06, 2017: e-Therapeutics : Appointment of Chief Executive Officer 44

Feb 16, 2017: e-Therapeutics Announces Directorate Change 45

Jan 09, 2017: e-Therapeutics: Appointment of Amgen Executive Director as Chief Executive 46

Section 6-Appendix 47

Methodology 47

Ratio Definitions 47

About GlobalData 51

Contact Us 51

Disclaimer 51

List of Figures

e-Therapeutics Plc, Performance Chart (2014-2018) 22

e-Therapeutics Plc, Ratio Charts 24

e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 26

List of Tables

e-Therapeutics Plc, Key Facts 5

e-Therapeutics Plc, Key Employees 6

e-Therapeutics Plc, Key Employee Biographies 7

e-Therapeutics Plc, Major Products and Services 8

e-Therapeutics Plc, History 9

e-Therapeutics Plc, Other Locations 11

e-Therapeutics Plc, Subsidiaries 11

e-Therapeutics Plc, Key Competitors 18

e-Therapeutics Plc, Ratios based on current share price 19

e-Therapeutics Plc, Annual Ratios 20

e-Therapeutics Plc, Annual Ratios (Cont...1) 21

e-Therapeutics Plc, Interim Ratios 23

e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26

e-Therapeutics Plc, Recent Deals Summary 27

Currency Codes 47

Capital Market Ratios 47

Equity Ratios 48

Profitability Ratios 48

Cost Ratios 49

Liquidity Ratios 49

Leverage Ratios 50

Efficiency Ratios 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Alliance Pharma Plc

Domainex Ltd

Oxford BioMedica Plc

Sentinel Oncology Ltd

Summit Therapeutics Plc

e-Therapeutics Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8916
Site License
USD 250 INR 17833
Corporate User License
USD 375 INR 26749



The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com